stockrowBeam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −16.7%
- Free cash flow
- −29.5%
Quarter to September 2026, against a year earlier
Follow BEAM
Alert me
Beam Therapeutics Inc. (BEAM) Net margin
Beam Therapeutics Inc.'s net margin over the twelve months to 30 September 2026 was −73.9%, down 16.6 percentage points from fiscal 2025 (−57.2%). Over the past ten years it has ranged from −816,120.8% (fiscal 2020) to 0.00% (fiscal 2018); the current reading is higher than 67% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | −57.2% | 535.89 |
| FY2024 | −593.1% | (558.04) |
| FY2023 | −35.1% | 439.45 |
| FY2022 | −474.5% | 240.37 |
| FY2021 | −714.9% | 815,405.92 |
| FY2020 | −816,120.8% | (310,343.05) |
| FY2019 | −505,777.8% | (505,777.78) |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | — |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Sep 2026 | −43,780.1% | (18,743.80) |
| Jun 2026 | −25,036.3% | (24,739.15) |
| Mar 2026 | −297.2% | (510.18) |
| Dec 2025 | 213.0% | 1,373.77 |
| 27 more quarters | Free account |
Against its own ten years
Net margin against peers
| Company | Net margin |
|---|---|
| MBX MBX Biosciences, Inc. compare | 0.00% |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −44.9% |
| BEAM Beam Therapeutics Inc. | −73.9% |
| XNCR Xencor, Inc. compare | −155.6% |
| RCUS Arcus Biosciences, Inc. compare | −453.0% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −789.9% |
| IDYA IDEAYA Biosciences, Inc. compare | −1,149.6% |
| VRDN Viridian Therapeutics, Inc. compare | −1,724.1% |
| TLX Telix Pharmaceuticals Limited compare | — |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 1.06% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on BEAM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement